A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!

Dr Pandey shares key insights on dosing, monitoring, and patient education to sustain therapy and improve outcomes. Essential for cardiologists and PCPs!

Adam Gilden, MD, MSCE, is an associate director of the Obesity Medicine Fellowship at University of Colorado School of Medicine and associate director of the Colorado University Medicine Weight ...

Background: Despite their potential, Glucagon-like peptide-1 receptor agonists (GLP-1 RA) have not been well studied in cardiac amyloidosis (CA) as randomized trials on GLP-1 RA have excluded patients ...

Source: LabXchange 2019 Molecular Homology compares DNA sequences and amino acid sequences between species to determine relatedness. This information can be represented as a phylogenetic tree that ...

Director Rishab Shetty and Hombale Films are leaving no stone unturned for the highly anticipated Kantara: Chapter 1. Production has commenced on the film’s climax, an elaborate war sequence ...

Share on Pinterest A new study compares the risks and benefits of using GLP-1 medications. Iuliia Burmistrova/Getty Images The use of glucagon-like peptide-1 receptor agonists (GLP-1 agonists ...

By increasing the abundance of this one gut microbe in diabetic mice, researchers led by a team at Jiangnan University in China have shown they can "orchestrate the secretion of glucagon-like ...

Formally, these drugs are known as glucagon-like peptide-1 receptor agonists (GLP-1RA) and include Mounjaro and Zepbound. Informally, media, patients and even some physicians have dubbed GLP-1 ...